HIP1-ALK-Rearranged Lung Cancer in a Young Adult With BRAF V600E Mutation Detected After ALK Tyrosine Kinase Inhibitor Therapy: A Case Report

Aiko Ogimoto; Naoko Katsurada; Atsuhiko Yatani; Chihiro Mimura; Masatsugu Yamamoto; Motoko Tachihara

doi:10.1016/j.jtocrr.2023.100612

HIP1-ALK-Rearranged Lung Cancer in a Young Adult With BRAF V600E Mutation Detected After ALK Tyrosine Kinase Inhibitor Therapy: A Case Report

JTO Clin Res Rep. 2023 Nov 25;5(1):100612. doi: 10.1016/j.jtocrr.2023.100612. eCollection 2024 Jan.

Authors

Aiko Ogimoto¹, Naoko Katsurada¹, Atsuhiko Yatani¹, Chihiro Mimura¹, Masatsugu Yamamoto¹, Motoko Tachihara¹

Affiliation

¹ Division of Respiratory Medicine, Department of Internal Medicine, Kobe University Graduate School of Medicine, Kobe, Japan.

Abstract

HIP1-ALK is a relatively rare fusion pattern in ALK-rearranged NSCLC. Existing studies on the efficacy of ALK tyrosine kinase inhibitor (TKI) resistance mechanisms and treatment strategies in HIP1-ALK-rearranged lung cancer are limited. Here, we report the case of an 18-year-old man with HIP1-ALK-rearranged adenocarcinoma who developed BRAF V600E and V1180L mutations after ALK TKI therapy, in whom the administration of BRAF and MEK inhibitors was ineffective. Brigatinib was effective after chemotherapy with cytotoxic drugs. Development of effective treatments is desirable for rare variants of ALK-rearranged lung cancer after acquiring resistance to ALK TKIs.

Keywords: BRAF V600E; Case report; HIP1-ALK; Lung adenocarcinoma; Resistance mechanism.

Publication types

Case Reports